title: E3 ubiquitin ligase Cbl-b potentiates the apoptotic action of arsenic trioxide by inhibiting the PI3K/Akt pathway.
abstract: Arsenic trioxide (ATO) is a strong inducer of apoptosis in malignant hematological cells. Inducible phosphatidyl inositol 3 kinase (PI3K)-Akt activation promotes resistance to ATO. In the present study, we evaluated whether E3 ubiquitin ligase Cbl-b, a negative regulator of PI3K activation, is involved in the action of ATO. The effect of ATO on cell viability was measured by the Trypan blue exclusion assay or by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was determined by flow cytometry and protein expression was assayed by Western blotting. ATO decreased the viability of HL60 cells and induced cellular apoptosis, which was accompanied by transient activation of Akt. The PI3K/Akt inhibitor, LY294002, significantly increased ATO-induced apoptosis (P < 0.05). In addition, ATO up-regulated the expression of Cbl-b proteins. Furthermore, ATO inhibited cell viability with an IC50 of 18.54 μM at 24 h in rat basophilic leukemia-2H3 cells. ATO induced cellular apoptosis with transient activation of Akt and Cbl-b was also up-regulated. Rat basophilic leukemia-2H3 cells transfected with a dominant negative (DN) Cbl-b mutation showed overexpression of Cbl-b (DN) and enhanced Akt activation. Compared with cells transfected with vector, ATO-induced apoptosis was decreased and G2/M phase cells were increased at the same concentration (P < 0.05). The PI3K/Akt inhibitor, LY294002, re-sensitized Cbl-b (DN) overexpressing cells to ATO and reversed G2/M arrest (P < 0.05). Taken together, these results suggest that Cbl-b potentiates the apoptotic action of ATO by inhibition of the PI3K/Akt pathway.
authors.affiliation: Department of Medical Oncology, China Medical University.
authors.forename: Li
authors.initials: L
authors.lastname: Yingchun
authors.forename: Qu
authors.initials: Q
authors.lastname: Xiujuan
authors.forename: Qu
authors.initials: Q
authors.lastname: Jinglei
authors.forename: Zhang
authors.initials: Z
authors.lastname: Ye
authors.forename: Liu
authors.initials: L
authors.lastname: Jing
authors.forename: Teng
authors.initials: T
authors.lastname: Yuee
authors.forename: Hu
authors.initials: H
authors.lastname: Xuejun
authors.forename: Hou
authors.initials: H
authors.lastname: Kezuo
authors.forename: Liu
authors.initials: L
authors.lastname: Yunpeng
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D015153:Blotting, Western; D005434:Flow Cytometry; D018922:HL-60 Cells; D006801:Humans; D010087:Oxides / Q000494:pharmacology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D050721:Proto-Oncogene Proteins c-cbl / Q000494:pharmacology*; D051381:Rats; D015398:Signal Transduction / Q000187:drug effects; D044767:Ubiquitin-Protein Ligases / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D001152:Arsenicals; D010087:Oxides; D000081082:Phosphoinositide-3 Kinase Inhibitors; D050721:Proto-Oncogene Proteins c-cbl; D044767:Ubiquitin-Protein Ligases; D051057:Proto-Oncogene Proteins c-akt; D000077237:Arsenic Trioxide